| 产品描述: | Povorcitinib (INCB54707) is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib is used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP). |
| 体外研究: |
Povorcitinib(60 mg/kg,口服,每日两次,共 16 天)可在携带 Dp16 唐氏综合征(DS)小鼠模型中降低血清中 MCP-1、IP-10、IFN-γ 和 TNF-α 的水平,降低肝损伤标志物丙氨酸氨基转移酶(ALT)和天冬氨酸氨基转移酶(AST)的表达,减轻小鼠的肝脏炎症和病理损伤,延长小鼠存活率。 |
| 体内研究: |
Povorcitinib 调节 TNF-α 和 TGF-β 的表达,从而表现出抗炎活性。 |
| 参考文献: |
1. Paul Smith, et al. Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp). Patent WO2021076124A1. 2. Kirby JS, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2023 Oct 21:S0190-9622(23)03037-2. 3. Zouboulis C C, et al. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment[J]. Journal of the European Academy of Dermatology and Venereology, 2024. 4. Tuttle KD, et al., JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome. Cell Rep. 2020 Nov 17;33(7):108407. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.971 ml |
9.853 ml |
19.706 ml |
| 5 mM |
0.394 ml |
1.971 ml |
3.941 ml |
| 10 mM |
0.197 ml |
0.985 ml |
1.971 ml |
| 50 mM |
0.039 ml |
0.197 ml |
0.394 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |